Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease

2025-523845-90-00 Protocol CRSP-AID-501 Human pharmacology (Phase I) - Other Authorised, recruitment pending

Status Authorised, recruitment pending · 2 EU/EEA countries · 4 sites · Protocol CRSP-AID-501

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruitment pending
Participants planned 60
Countries 2
Sites 4

Relapsed/Refractory Hematologic Autoimmune Disease

Key facts

Sponsor
CRISPR Therapeutics AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Decision date (initial)
2026-03-12
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2025-523845-90-00
WHO UTN
U1111-1328-3996

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Relapsed/Refractory Hematologic Autoimmune Disease

VersionLevelCodeTermSystem organ class
27.0 LLT 10087092 Warm autoimmune hemolytic anemia 100000004848
23.0 LLT 10074667 Immune thrombocytopenic purpura 10005329

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

CRISPR Therapeutics AG

Sponsor organisation
CRISPR Therapeutics AG
Address
Baarerstrasse 14
City
Zug
Postcode
6300
Country
Switzerland

Scientific contact point

Organisation
CRISPR Therapeutics AG
Contact name
Medical Affairs

Public contact point

Organisation
CRISPR Therapeutics AG
Contact name
Medical Affairs

Locations

2 EU/EEA countries · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Authorised, recruitment pending 30 3
Spain Authorised, recruitment pending 15 1
Rest of world
United States
15

Investigational sites

Germany

3 sites · Authorised, recruitment pending
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
II. Medizinische Klinik und Poliklinik, Langenbeckstrasse 1, Oberstadt, Mainz
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Carl-Neuberg-Strasse 1, Gross Buchholz, Hanover
Universitaetsklinikum Koeln AöR
Innere Medizin I, Kerpener Strasse 62, Lindenthal, Cologne

Spain

1 site · Authorised, recruitment pending
Hospital Universitario Reina Sofia
Hematology, Avenida Menendez Pidal S/n, 14004, Cordoba

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-31 Germany Acceptable with conditions
2026-03-09
2026-03-12
2 SUBSTANTIAL MODIFICATION SM-1 2026-03-19 Germany Acceptable with conditions 2026-04-29
3 SUBSTANTIAL MODIFICATION SM-2 2026-03-24 Acceptable with conditions 2026-04-21
4 NON SUBSTANTIAL MODIFICATION NSM-1 2026-05-07 Germany Acceptable with conditions 2026-05-07